Silo Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.91
- Today's High:
- $1.991
- Open Price:
- $1.93
- 52W Low:
- $1.71
- 52W High:
- $9
- Prev. Close:
- $1.97
- Volume:
- 4986
Company Statistics
- Market Cap.:
- $6.28 million
- Book Value:
- 2.675
- Revenue TTM:
- $72102
- Operating Margin TTM:
- -6275.25%
- Gross Profit TTM:
- $66260
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.32%
- Return on Equity TTM:
- -56.47%
Company Profile
Silo Pharma Inc had its IPO on 2014-05-13 under the ticker symbol SILO.
The company operates in the Healthcare sector and Biotechnology industry. Silo Pharma Inc has a staff strength of 3 employees.
Stock update
Shares of Silo Pharma Inc opened at $1.93 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.91 - $1.99, and closed at $1.97.
This is a 0% increase from the previous day's closing price.
A total volume of 4,986 shares were traded at the close of the day’s session.
In the last one week, shares of Silo Pharma Inc have slipped by -2.48%.
Silo Pharma Inc's Key Ratios
Silo Pharma Inc has a market cap of $6.28 million, indicating a price to book ratio of 0.8553 and a price to sales ratio of 140.6109.
In the last 12-months Silo Pharma Inc’s revenue was $72102 with a gross profit of $66260 and an EBITDA of $0. The EBITDA ratio measures Silo Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Silo Pharma Inc’s operating margin was -6275.25% while its return on assets stood at -29.32% with a return of equity of -56.47%.
In Q2, Silo Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Silo Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.61 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Silo Pharma Inc’s profitability.
Silo Pharma Inc stock is trading at a EV to sales ratio of 68.6593 and a EV to EBITDA ratio of 1.2134. Its price to sales ratio in the trailing 12-months stood at 140.6109.
Silo Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $10.25 million
- Total Liabilities
- $1.12 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Silo Pharma Inc ended 2024 with $10.25 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.25 million while shareholder equity stood at $8.30 million.
Silo Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $1.12 million in other current liabilities, 311.00 in common stock, $-9090475.00 in retained earnings and $0 in goodwill. Its cash balance stood at $158832.00 and cash and short-term investments were $9.99 million. The company’s total short-term debt was $-1,048,090 while long-term debt stood at $0.
Silo Pharma Inc’s total current assets stands at $10.18 million while long-term investments were $0 and short-term investments were $9.83 million. Its net receivables were $68390.00 compared to accounts payable of $1.05 million and inventory worth $0.
In 2024, Silo Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Silo Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.97
- 52-Week High
- $9
- 52-Week Low
- $1.71
- Analyst Target Price
- $
Silo Pharma Inc stock is currently trading at $1.97 per share. It touched a 52-week high of $9 and a 52-week low of $9. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $2.03 and 200-day moving average was $2.36 The short ratio stood at 0.19 indicating a short percent outstanding of 0%.
Around 1483.3% of the company’s stock are held by insiders while 275.9% are held by institutions.
Frequently Asked Questions About Silo Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company’s developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer’s, Parkinson’s, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.